Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 2CNS 2

Conditions

Carcinoma, Hepatocellular 147Carcinoma, Renal Cell 37Parkinson Disease 4, Autosomal Dominant Lewy Body 31Neoplasms 28Cholangiocarcinoma 26Endometrial Neoplasms 19Thyroid Neoplasms 17Liver Neoplasms 17Melanoma 15Stomach Neoplasms 13Carcinoma, Non-Small-Cell Lung 13Biliary Tract Neoplasms 13Recurrence 9Neoplasm Metastasis 9Squamous Cell Carcinoma of Head and Neck 8Ovarian Neoplasms 8Breast Neoplasms 8Uterine Cervical Neoplasms 7Triple Negative Breast Neoplasms 5Thyroid Carcinoma, Anaplastic 5Small Cell Lung Carcinoma 5Neuroendocrine Tumors 5Esophageal Squamous Cell Carcinoma 5Colorectal Neoplasms 5Pancreatic Neoplasms 4Kidney Neoplasms 4Carcinoma, Transitional Cell 4Carcinoma 4Adenocarcinoma 4Thyroid Cancer, Papillary 3

Interventions

lenvatinib 2Temozolomide 2temsirolimus 1penpulimab 1pazopanib 1cabozantinib 1anlotinib 1Vorinostat 1Vinorelbine 1Sirolimus 1Restraint, Physical 1Everolimus 1Absorptiometry, Photon 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Paraganglioma, Extra-Adrenal × lenvatinib × Clear all
NCT02592356 2024-03-05

Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer

M.D. Anderson Cancer Center

Phase NA Completed
23 enrolled
CNSEndocrine

Paraganglioma, Extra-Adrenal, Carcinoma, Medullary

NCT03008369 2024-02-20

Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery

Mayo Clinic

Phase 2 Completed
3 enrolled 9 charts
CNSEndocrine

Paraganglioma, Extra-Adrenal, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡